RIPE-KG · Version 1.1.0 · Resource
ripekg:work/RIPEWDC6530C77C166694
https://w3id.org/ripe/ripe-kg/work/RIPEWDC6530C77C166694
| Subject | Predicate | Object |
|---|---|---|
ripekg:work/10.1136%2Fbmj-2025-084314Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEWDC6530C77C166694Safety, tolerability, and efficacy of mezagitamab (TAK-079) in chronic or persistent primary immune thrombocytopenia: Interim results from a phase 2, randomized, double-blind, placebo-controlled study |
ripekg:work/RIPEWDC6530C77C166694Safety, tolerability, and efficacy of mezagitamab (TAK-079) in chronic or persistent primary immune thrombocytopenia: Interim results from a phase 2, randomized, double-blind, placebo-controlled study |
dcterms:title |
Safety, tolerability, and efficacy of mezagitamab (TAK-079) in chronic or persistent primary immune thrombocytopenia: Interim results from a phase 2, randomized, double-blind, placebo-controlled study |
ripekg:work/RIPEWDC6530C77C166694Safety, tolerability, and efficacy of mezagitamab (TAK-079) in chronic or persistent primary immune thrombocytopenia: Interim results from a phase 2, randomized, double-blind, placebo-controlled study |
rdf:type |
node1 |
ripekg:work/RIPEWDC6530C77C166694Safety, tolerability, and efficacy of mezagitamab (TAK-079) in chronic or persistent primary immune thrombocytopenia: Interim results from a phase 2, randomized, double-blind, placebo-controlled study |
rdf:type |
http://purl.org/spar/fabio/Work |
ripekg:work/RIPEWDC6530C77C166694Safety, tolerability, and efficacy of mezagitamab (TAK-079) in chronic or persistent primary immune thrombocytopenia: Interim results from a phase 2, randomized, double-blind, placebo-controlled study |
rdf:type |
rdfs:Resource |
ripekg:work/RIPEWDC6530C77C166694Safety, tolerability, and efficacy of mezagitamab (TAK-079) in chronic or persistent primary immune thrombocytopenia: Interim results from a phase 2, randomized, double-blind, placebo-controlled study |
rdf:type |
owl:Thing |
ripekg:work/RIPEWDC6530C77C166694Safety, tolerability, and efficacy of mezagitamab (TAK-079) in chronic or persistent primary immune thrombocytopenia: Interim results from a phase 2, randomized, double-blind, placebo-controlled study |
rdf:type |
prov:Entity |
ripekg:work/RIPEWDC6530C77C166694Safety, tolerability, and efficacy of mezagitamab (TAK-079) in chronic or persistent primary immune thrombocytopenia: Interim results from a phase 2, randomized, double-blind, placebo-controlled study |
rdf:type |
ripe:WorkWork |